NDAINTRAVENOUSSOLUTION
Approved
Jun 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
CYCLOPHOSPHAMIDE (cyclophosphamide injection, solution) by Baxter International is characterized. Approved for lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma and 4 more indications. First approved in 2023.
Drug data last refreshed 15h ago · AI intelligence enriched 18h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Cyclophosphamide is an intravenous alkylating agent that cross-links tumor cell DNA to inhibit growth of rapidly proliferating malignant cells. It is indicated for treatment of lymphomas (lymphocytic, mixed-cell, histiocytic, and Burkitt's), myeloma, and leukemia. The drug works by interfering with susceptible cancer cell proliferation through active alkylating metabolites.
Growth
Early-stage growth asset with 507 linked positions indicates expanding commercial infrastructure and significant team-building opportunity across IT, Commercial, and Engineering functions.
Mechanism of Action
characterized. However, cross-linking of tumor cell DNA may be involved. The active alkylating metabolites of cyclophosphamide interfere with the growth of susceptible rapidly proliferating malignant cells.
Worked on CYCLOPHOSPHAMIDE at Baxter International? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.